Why the study?
Do anti-citrullinated protein antibodies provide better diagnostic and prognostic value than rheumatoid factor in rheumatoid arthritis?
Do anti-citrullinated protein antibodies provide better diagnostic and prognostic value than rheumatoid factor in rheumatoid arthritis?
Answers are grounded in this paper and cite their sources.
ACPAs, particularly anti-Sa/anti-MCV, offer superior diagnostic and prognostic value compared to traditional rheumatoid factor in rheumatoid arthritis.
Antibodies to citrullinated proteins/peptides (ACPAs) are the second serological marker to have recently been included in the 2010 ACR/EULAR Rheumatoid Arthritis (RA) Classification Criteria, which are focused on early diagnosis and therapy. This review discusses their history and some clinical aspects of ACPAs, focusing on the diagnostic utility of anti-cyclic citrullinated peptide (anti-CCP) antibodies as a marker of RA as compared to the widely used rheumatoid factor (RF). Simultaneously, this review aims to raise physician awareness and interest in anti-citrullinated vimentin antibody (anti-Sa/anti-MCV), another member of the ACPA family, which appears to have a better predictive value as a marker of RA than anti-CCP or RF and correlates closely with disease activity and therapeutic response among patients with RA.
No takes yet. Share an insight, caveat, or question.
Puszczewicz et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: